Cited by 159Nanoparticle-Based Drug DeliveryNanotechnology research and applicationsRadiopharmaceutical Chemistry and Applications

Advantages and Limitations of Current Techniques for Analyzing the Biodistribution of Nanoparticles

Open access
Arms, Lauren, Smith, Doug W., Flynn, Jamie, Palmer, William, Martin, Antony, Woldu, Ameha, Hua, Susan·2018·Frontiers in Pharmacology

Abstract

Nanomedicines are typically submicrometer-sized carrier materials (nanoparticles) encapsulating therapeutic and/or imaging compounds that are used for the prevention, diagnosis and treatment of diseases. They are increasingly being used to overcome biological barriers in the body to improve the way we deliver compounds to specific tissues and organs. Nanomedicine technology aims to improve the balance between the efficacy and the toxicity of therapeutic compounds. Nanoparticles, one of the key technologies of nanomedicine, can exhibit a combination of physical, chemical and biological characteristics that determine their in vivo behavior. A key component in the translational assessment of nanomedicines is determining the biodistribution of the nanoparticles following in vivo administration in animals and humans. There are a range of techniques available for evaluating nanoparticle biodistribution, including histology, liquid scintillation counting (LSC), indirectly measuring drug concentrations, in vivo optical imaging, computed tomography (CT), magnetic resonance imaging (MRI), and nuclear medicine imaging. Each technique has its own advantages and limitations, as well as capabilities for assessing real-time, whole-organ and cellular accumulation. This review will address the principles and methodology of each technique and their advantages and limitations for evaluating in vivo biodistribution of nanoparticles.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fphar.2018.00802

Cites

166 of 166 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Dynamic contrast-enhanced CT has been utilized to evaluate intratumoral perfusion, permeability, and aggregation of CT contrast agent-carrying NPs in tumors in mice.

    “However, dynamic contrast-enhanced (DCE)CT has been utilized to evaluate the intratumoral perfusion, permeability, and aggregation of CT contrast agent-carrying NPs in tumors in mice [19,132,133].”

    From Approaches to Improve EPR-Based Drug Delivery for Cancer Therapy and Diagnosis (2023) · cites this paper as [133]

    The Computed tomography (CT) section (page unavailable) says CT has been used for real-time, in vivo imaging of nanoparticles carrying contrast agents, including repeated imaging in animals. It does not describe dynamic contrast-enhanced CT measuring intratumoral perfusion, permeability, or nanoparticle aggregation in mouse tumors. (LLM, conf=0.85)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Arms, L., Smith, D. W., Flynn, J., Palmer, W., Martin, A., Woldu, A., & Hua, S.
Affiliations
  • University of Newcastle Australia (AU)
  • Hunter Medical Research Institute (AU)
Corresponding author
Hua, Susan
Venue
Frontiers in Pharmacology
Published
2018-08-14
Volume
9
Pages
802-802
ISSN
1663-9812 (ISSN-L)
OpenAlex
W2885328264
Cited by
159
References
166
Citations by year
2026: 15 · 2025: 31 · 2024: 23 · 2023: 18 · 2022: 17 · 2021: 29 · 2020: 18 · 2019: 8
FWCI
0.91
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Pharmacology (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • NOVA (University of Newcastle Australia) (submittedVersion)
Funders
Rebecca L. Cooper Medical Research Foundation
Topics
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Physical Sciences › Engineering › Biomedical Engineering › Nanotechnology research and applications
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
Keywords
nanoparticle biodistribution, nanomedicine, in vivo imaging, liquid scintillation counting, in vivo optical imaging, computed tomography, magnetic resonance imaging, scintigraphy, histology, nanoparticle accumulation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review